Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by Cantor Fitzgerald
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 136.49% from the company’s previous […]
More Stories
Ukraine Reports Crash of One of Its F-16s, Pilot Safe
By Victoria Friedman The Armed Forces of Ukraine said one of its F-16 fighter jets had crashed, and that the...
US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions US Gas Prices Remain Elevated Amid Ongoing Middle East Tensions
By Naveen Athrappully Gasoline prices in the United States continue to remain high at over $4 per gallon as the...
Spain’s Ceuta Overwhelmed as Nearly 60,000 Illegal Immigrants Cross From Morocco in a Day
By Owen Evans Ceuta was overwhelmed overnight as the Spanish North African exclave faced a fresh wave of nearly 60,000...
Spain’s Mass Illegal Immigration Crisis: What to Know
By Troy Myers Tens of thousands of illegal immigrants crossed from Morocco into Spain in a single day, igniting worldwide...
Weekly Unemployment Claims Remain at Historically Low Levels
By Andrew Moran The number of Americans applying for unemployment benefits remained at historically low levels last week, as layoffs...
US Government Acquires Equity Stakes in 7 More Companies
By Andrew Moran The Department of Commerce said on July 29 it will allocate $874 million in incentives to bolster...